Market Cap : 181.84 M | Enterprise Value : 119.89 M | PE Ratio : At Loss | PB Ratio : 2.91 |
---|
NAS:VTGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VTGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
VistaGen Therapeutics's Total Assets for the quarter that ended in Mar. 2022 was $74.64 Mil.
During the past 12 months, VistaGen Therapeutics's average Total Assets Growth Rate was 25.80% per year. During the past 3 years, the average Total Assets Growth Rate was 92.50% per year. During the past 5 years, the average Total Assets Growth Rate was 64.20% per year. During the past 10 years, the average Total Assets Growth Rate was 44.20% per year.
During the past 13 years, VistaGen Therapeutics's highest 3-Year average Total Assets Growth Rate was 539.10%. The lowest was -8.50%. And the median was 65.10%.
Total Assets is connected with ROA %. VistaGen Therapeutics's annualized ROA % for the quarter that ended in Mar. 2022 was -80.82%. Total Assets is also linked to Revenue through Asset Turnover. VistaGen Therapeutics's Asset Turnover for the quarter that ended in Mar. 2022 was 0.00.
The historical data trend for VistaGen Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
VistaGen Therapeutics's Total Assets for the fiscal year that ended in Mar. 2022 is calculated as
Total Assets | = | Total Equity (A: Mar. 2022 ) | + | Total Liabilities (A: Mar. 2022 ) |
= | 64.715 | + | 9.928 | |
= | 74.64 |
VistaGen Therapeutics's Total Assets for the quarter that ended in Mar. 2022 is calculated as
Total Assets | = | Total Equity (Q: Mar. 2022 ) | + | Total Liabilities (Q: Mar. 2022 ) |
= | 64.715 | + | 9.928 | |
= | 74.64 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Assets is connected with ROA %.
VistaGen Therapeutics's annualized ROA % for the quarter that ended in Mar. 2022 is
ROA % | = | Net Income (Q: Mar. 2022 ) | / | ( (Total Assets (Q: Dec. 2021 ) | + | Total Assets (Q: Mar. 2022 )) | / count ) |
= | -66.752 | / | ( (90.536 | + | 74.643) | / 2 ) | |
= | -66.752 | / | 82.5895 | ||||
= | -80.82 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2022) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
VistaGen Therapeutics's Asset Turnover for the quarter that ended in Mar. 2022 is
Asset Turnover | ||||||
= | Revenue (Q: Mar. 2022 ) | / | ( (Total Assets (Q: Dec. 2021 ) | + | Total Assets (Q: Mar. 2022 )) | / count ) |
= | 0.039 | / | ( (90.536 | + | 74.643) | / 2 ) |
= | 0.039 | / | 82.5895 | |||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of VistaGen Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Saxe Jon S | director | FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076 |
Dotson Jerrold Duane | officer: VP, CFO AND SECRETARY | 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035 |
Singh Shawn | director, officer: CHIEF EXECUTIVE OFFICER | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Snodgrass H. Ralph | director, officer: PRES./CHIEF SCIENTIFIC OFFICER | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Smith Mark Alan | officer: CHIEF MEDICAL OFFICER | 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Mcpartland Mark A. | officer: VP CORPORATE DEVELOPMENT | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Gin Jerry B | director | 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080 |
Underdown Brian J. | director | C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000 |
Cunningham Ann Michelle | director | 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335 |
Rice A. Franklin | officer: VP CORPORATE DEVELOPMENT | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Bonfiglio Gregory A. | director | 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 |
Cato Holding Co | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Cato Allen Easley | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Jones Stephanie | director, 10 percent owner, officer: PRESIDENT | 13834 W. HOYT ROAD RATHDRUM ID 83858 |
From GuruFocus
Other Sources
By Seekingalpha 2022-02-10
By Zacks 2022-04-05
By Zacks 2021-02-11
By Zacks 2022-02-10
By Zacks 2021-10-20
By Seekingalpha 2021-06-29
By Fool 2021-06-30
By Zacks 2021-08-12
By Zacks 2021-03-11
By tipranks.com 2022-03-03
By Seekingalpha 2021-11-10
By tipranks.com 2022-02-13